Breast Cancer Surgery clinical trials

New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer

This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.

Lifestyle and energy in breast cancer survivors

This study looks at how lifestyle and energy levels affect women recently diagnosed with early-stage breast cancer. It may help researchers understand the body's changes during treatment.

Music Therapy to Help Breast Cancer Patients During Chemotherapy

This study tests whether music therapy can help women with breast cancer feel better during chemotherapy after surgery. Researchers will see if listening to or participating in music sessions improves quality of life and reduces stress during treatment.

Comparing elacestrant to standard hormone therapy for high-risk early breast cancer

This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.

Vaccine with hormone therapy or chemo for advanced breast cancer

This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.

Registry for young women with certain early breast cancer treatments

This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.

Vaccine with chemotherapy for advanced triple-negative breast cancer

This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.

Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer

This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.

Ivermectin with immunotherapy for metastatic triple-negative breast cancer

This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.

Pembrolizumab plus ADG106 for advanced triple-negative breast cancer

This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.

ILB-2109 plus toripalimab for advanced solid cancers

This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.

CAR-T therapy for CEA-positive advanced cancers

This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.

High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc

This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.

Personalized cancer vaccine with standard therapy for triple-negative breast cancer

This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.

Remote exercise program for cancer survivors

This study tests a remote guided exercise program for cancer survivors to see if it helps with recovery and well-being. It is designed for people who have finished their main cancer treatments and are not already exercising a lot.

Harvesting Cancer Cells for Experimental Treatment

This trial collects immune cells from cancer patients or healthy volunteers to develop new experimental cancer treatments. Researchers will take a sample of your tumor or blood cells, grow them in the lab, and study how to use them to fight your cancer.

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

Radiation after lumpectomy for node-negative breast cancer

This trial studies whether a specific radiation approach after lumpectomy can be helpful for certain people with early breast cancer that did not spread to lymph nodes at diagnosis. It focuses on people who finish neoadjuvant (before-surgery) treatment and reach a full response on final pathology.

Pyrotinib after breast cancer therapy for HER2-positive early disease

This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.

Reversing immune resistance in HER2-negative breast cancer

This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.

A RNA vaccine for stage 2-3 triple negative breast cancer

This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.

Re-irradiation with or without hyperthermia, or surgery only for recurrent breast cancer

This trial compares three treatment options for breast cancer that has come back in the chest or lymph nodes after previous radiation. It looks at adding hyperthermia (heating the tumor area) to re-irradiation, versus just re-irradiation or surgery alone, to see which offers better quality of life and survival with fewer side effects.

Local treatment for breast cancer spread to the liver

This study tests a local (targeted) approach for breast cancer that has spread to the liver. It looks at whether treating liver metastases with planned liver surgery, along with standard cancer treatment before and after, can improve outcomes.

Trial for brain metastases from triple-negative breast cancer

This Phase 2 study tests a treatment for people with triple-negative breast cancer that has spread to the brain. It’s designed for situations where the cancer can’t be safely cured with surgery or focused radiation.